Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13114675 | 0.87 | CNR1 (0.66) | CNR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14540422 | 0.87 | CNR1 (0.43) | CNR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14540458 | 0.85 | CNR1 (0.73) | CNR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13114626 | 0.83 | CNR1 (0.65) | CNR1CYP3A4CYP2C9CYP2C19RIPK3 | |
| SCHEMBL14540802 | 0.82 | CNR1 (0.54) | CNR1CYP3A4CYP2C9CYP2C19P2RX3 | |
| SCHEMBL13114631 | 0.82 | NOTUM (0.45) | CNR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13114636 | 0.82 | CNR1 (0.44) | CNR1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10305392 | 0.81 | CNR1 (0.52) | CNR1CYP3A4CYP2C9CYP2C19P2RX3 | |
| SCHEMBL13114619 | 0.81 | CNR1 (0.72) | CNR1CYP3A4CYP2C9CYP2C19P2RX3 | |
| SCHEMBL14540806 | 0.81 | CNR1 (0.49) | CNR1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816357-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816357-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816357-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1697371-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1697371-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1697371-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050171110-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-04 | — | — | US | disclosed |
| WO-2005063762-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171110-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | CNR1 1/4885CYP3A4 616/4885CYP2C9 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.